Samsung Biologics agrees development contract with STCube for anti-cancer candidate

3 Mar 2020

Samsung Biologics has signed a development and manufacturing service agreement with local biotech firm, STCube, for the latter’s anti-cancer drug candidate, STT-003, the South Korean CDMO said Tuesday.

Under the agreement, Samsung Biologics will provide cell line development, process development, manufacturing of non-clinical and clinical material, and Investigational New Drug (IND) submission for STCube.

Samsung Biologics agrees development contract with STCube for anti-cancer candidate

The firms said the it took just two weeks of discussion before the contract was signed.

Due to the antibody STT-003 having a high expression over the surfaces of immune and cancer cells, suppressing their immune functions, therapies targeting STT-003 are expected to exhibit more favourable anti-cancer effects than conventional PD-1/PD-L1 therapies.

STCube plans to submit an IND on STT-003 in 2021, for use in both monotherapy and combination therapy.

Hyun-Jin Jung, CEO of STCube said the agreement paved the way for “stable implementation” of clinical trials in the US.

“So far, several globally recognized immunologists have agreed to serve on the scientific advisory board for phase I clinical studies of STT-003 antibody, including the head of clinical research at a world leading clinical institution for cancer treatment,” he said.